Page last updated: 2024-08-25

ljc 10627 and Blood Poisoning

ljc 10627 has been researched along with Blood Poisoning in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Bae, JS; Baek, MC; Choo, S; Kim, J; Sim, H	1
Fujiue, Y; Ikawa, K; Ikeda, K; Kaneko, K; Kuwabara, M; Morikawa, N; Morikawa, S; Suyama, H; Yamanoue, T	1
Arata, J; Baba, S; Hara, K; Hayasi, K; Kawada, Y; Matsuda, S; Matsumoto, F; Ooishi, M; Sasaki, J; Shinagawa, N; Sugihara, T	1

Trials

1 trial(s) available for ljc 10627 and Blood Poisoning

Article	Year
[Clinical evaluation of biapenem in various infectious diseases]. The Japanese journal of antibiotics, 1999, Volume: 52, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Cellulitis; Cholangitis; Cholecystitis; Drug Evaluation; Eye Diseases; Female; Genital Diseases, Female; Humans; Lymphangitis; Male; Middle Aged; Mouth Diseases; Osteomyelitis; Peritonitis; Pneumonia; Respiratory Tract Infections; Sepsis; Thienamycins; Tonsillitis; Urinary Tract Infections; Wounds and Injuries	1999

Article

Year

[Clinical evaluation of biapenem in various infectious diseases].

The Japanese journal of antibiotics, 1999, Volume: 52, Issue:11

Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Cellulitis; Cholangitis; Cholecystitis; Drug Evaluation; Eye Diseases; Female; Genital Diseases, Female; Humans; Lymphangitis; Male; Middle Aged; Mouth Diseases; Osteomyelitis; Peritonitis; Pneumonia; Respiratory Tract Infections; Sepsis; Thienamycins; Tonsillitis; Urinary Tract Infections; Wounds and Injuries

1999

Other Studies

2 other study(ies) available for ljc 10627 and Blood Poisoning

Article	Year
Biapenem reduces sepsis mortality via barrier protective pathways against HMGB1-mediated septic responses. Pharmacological reports : PR, 2021, Volume: 73, Issue:3 Topics: Animals; Cell Movement; Cells, Cultured; Disease Models, Animal; HMGB1 Protein; Human Umbilical Vein Endothelial Cells; Humans; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Sepsis; Signal Transduction; Thienamycins	2021
Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration. The Japanese journal of antibiotics, 2008, Volume: 61, Issue:5 Topics: Acute Kidney Injury; Adult; Aged; Critical Illness; Drosophila Proteins; Drug Resistance, Bacterial; Female; Hemodiafiltration; Humans; Infusions, Intravenous; Male; Middle Aged; Monte Carlo Method; Nerve Tissue Proteins; Nuclear Proteins; Pseudomonas aeruginosa; Sepsis; Therapeutic Equivalency; Thienamycins; Time Factors; Transcription Factors	2008

Article

Year

Biapenem reduces sepsis mortality via barrier protective pathways against HMGB1-mediated septic responses.

Pharmacological reports : PR, 2021, Volume: 73, Issue:3

Topics: Animals; Cell Movement; Cells, Cultured; Disease Models, Animal; HMGB1 Protein; Human Umbilical Vein Endothelial Cells; Humans; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Sepsis; Signal Transduction; Thienamycins

2021

Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration.

The Japanese journal of antibiotics, 2008, Volume: 61, Issue:5

Topics: Acute Kidney Injury; Adult; Aged; Critical Illness; Drosophila Proteins; Drug Resistance, Bacterial; Female; Hemodiafiltration; Humans; Infusions, Intravenous; Male; Middle Aged; Monte Carlo Method; Nerve Tissue Proteins; Nuclear Proteins; Pseudomonas aeruginosa; Sepsis; Therapeutic Equivalency; Thienamycins; Time Factors; Transcription Factors

2008